Evidence map›Paper›PMID 32289314›Full record

ArticleExperimental neurology2020

Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke.

Pranay Srivastava, Chunxia G Cronin, Victoria L Scranton, Kenneth A Jacobson, Bruce T Liang, Rajkumar Verma

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 98 citations in OpenAlex.

  1. Trial
  2. Novel P2X4 Receptor Antagonist MRS4719 Improves Ischemia/reperfusion Injury in Mice.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. [Mechanisms of spinal microglia and astrocytes in exercise-induced analgesia].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Species Differences of P2X4 Receptor Modulators.ACS pharmacology & translational science · 2025
    Article
  11. Article
  12. International journal of molecular sciences · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Role of HDAC5 Epigenetics in Chronic Craniofacial Neuropathic Pain.International journal of molecular sciences · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pranay SrivastavaDepartment of Neuroscience, UConn Health, Farmington, CT 06032, USA.
Chunxia G CroninCalhoun Cardiology Center, UConn Health, Farmington, CT 06032, USA.
Victoria L ScrantonDepartment of Neuroscience, UConn Health, Farmington, CT 06032, USA.
Kenneth A JacobsonNational Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892-0810, USA.
Bruce T LiangCalhoun Cardiology Center, UConn Health, Farmington, CT 06032, USA.
Rajkumar VermaDepartment of Neuroscience, UConn Health, Farmington, CT 06032, USA. Electronic address: raverma@uchc.edu.
UConn Health · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Development of Drugs Acting at Ion ChannelsZIADK031127 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$3.9M
PURINERGIC SIGNALING IN CULTURED HEART CELLSR01HL048225 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LIANG, BRUCE T · 1993 to 2005
$1.9M
American Heart Association-American Stroke Association 18CDA34110011NHLBI NIH HHS R01 HL048225
6 · The paper itself

Abstract

Stroke remains a leading cause of disability in the United States. Despite recent advances, interventions to reduce damage and enhance recovery after stroke are lacking. P2X4R, a receptor for adenosine triphosphate (ATP), regulates activation of myeloid immune cells (infiltrating monocytes/macrophages and brain-resident microglia) after stroke injury. However, over-stimulation of P2X4Rs due to excessive ATP release from dying or damaged neuronal cells can contribute to ischemic injury. Therefore, we pharmacologically inhibited P2X4R to limit the over-stimulated myeloid cell immune response and improve both acute and chronic stroke recovery. We subjected 8-12-week-old male and female wild type mice to a 60 min right middle cerebral artery occlusion (MCAo) followed by 3 or 30 days of reperfusion. We performed histological, RNA sequencing, behavioral (sensorimotor, anxiety, and depressive), and biochemical (Evans blue dye extravasation, western blot, quantitative PCR, and flow cytometry) analyses to determine the acute (3 days after MCAo) and chronic (30 days after MCAo) effects of P2X4R antagonist 5-BDBD (1 mg/kg P.O. daily x 3 days post 4 h of MCAo) treatment. 5-BDBD treatment significantly (p < .05) reduced infarct volume, neurological deficit (ND) score, levels of cytokine interleukin-1 beta (IL-1β) and blood brain barrier (BBB) permeability in the 3-day group. Chronically, 5-BDBD treatment also conferred progressive recovery (p < .05) of motor balance and coordination using a rotarod test, as well as reduced anxiety-like behavior over 30 days. Interestingly, depressive-type behavior was not observed in mice treated with 5-BDBD for 3 days. In addition, flow cytometric analysis revealed that 5-BDBD treatment decreased the total number of infiltrated leukocytes, and among those infiltrated leukocytes, pro-inflammatory cells of myeloid origin were specifically reduced. 5-BDBD treatment reduced the cell surface expression of P2X4R in flow cytometry-sorted monocytes and microglia without reducing the total P2X4R level in brain tissue. In summary, acute P2X4R inhibition protects against ischemic injury at both acute and chronic time-points after stroke. Reduced numbers of infiltrating pro-inflammatory myeloid cells, decreased surface P2X4R expression, and reduced BBB disruption are likely its mechanism of neuroprotection and neuro-rehabilitation.

Indexed as

AnimalsBenzodiazepinonesDose-Response Relationship, DrugFemaleHEK293 CellsHumansIschemic StrokeMaleMiceMice, Inbred C57BLNeuroprotectionNeuroprotective AgentsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X45-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-oneBenzodiazepinonesNeuroprotective AgentsP2RX4 protein, humanPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X4

Identifiers

PMID32289314
PMCPMC7242087
OpenAlexW3015653345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.